ZHEJIANG MEIHUA DINGCHANG PHARMACEUTICAL CO.,LTD.

Founded in 2011，MHDC focus on the research and development of novel pharmaceutical drugs, and manufacture of high-difficulty drug dosage forms and medical devices. Up to now, the company's core business has expanded to the R&D and manufacture of Microsphere/Microcrystal, Solid Extended-Release Drugs, Extended-Release Injectables, Class-1 Medical Devices and new drugs, including minocycline hydrochloride ER tablets, exenatide/liraglttide ER microspheres, proteasome inhibitors, anti-tumor innovative drugs, nasal dressings and other products. The company is positioned as a R & D enterprise. While adhering to the independent research and development of the core pipeline, it uses its own unique microsphere preparation research and development platform to carry out extensive research and development project cooperation (CRO) with well-known pharmaceutical enterprises at both domestic and foreign countries to meet part of the current cash flow needs and maintain the right to share profits from the marketing of future products One of the company's high-value medical devices,“Dissolvable Nasal Dressing(Nasasponge)”has successfully obtained FDA medical device registration number，It will be available in the United States in 2023。Class 3 of domestic medical clinical applications have been completed，Clinical trials will also be completed in the first half of 2023. Minocycline Hydrochloride Extended-Release Tablet has been successfully submitted to ANDA and received preliminary confirmation by FDA review, and will be sold in the United States in 2023. Domestic import registration is under way. The construction of the company's first GMP production line of Microsphere LAR has been basically completed, which can not only ensure the industrialization of the company's microsphere products, but also undertake the cooperation projects of other pharmaceutical enterprises. A total of 10,000㎡ of modern standard factory building, plans to build all kinds of production lines in line with the international cGMP standard in the future, used to ensure the industrialization of the company's products The local government has provided the company with more than 50 million yuan of industrialization support, including plant and equipment decoration subsidies, preparation research and development milestone awards, tax relief, etc The company has a team of 45 person, including nearly 30 R&D personnel. Our major team members, who have studied and worked in famous overseas universities and pharmaceutical companies, have rich knowledge and experiences in global advanced formulation/device technology/cGMP. Several members are elected as Zhejiang Provincial Overseas Experts. Since its establishment, the company has obtained several rounds of financing from listed companies, government guide funds and well-known investment institutions, mainly used for production line construction, product research and development, clinical trials, market promotion, etc.